NASDAQ · Biotechnology

HURA (HURA) Stock

$2.09 -2.34% NASDAQ: HURA Healthcare

Valuation

MetricValue
Price$2.09
Market Cap$133.10M
P/E Ratio-3.75
P/B Ratio6.54
P/S Ratio0.00
EPS (TTM)$-0.63
52-Week High$3.90
52-Week Low$0.41
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-187.16%
ROA-81.88%
ROCE-152.38%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio0.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-23.0M$-15.0M$-8.0M$-18.0M$-32.0M
Net Profit$-23.0M$-15.0M$-8.0M$-22.0M$-30.0M
EPS$-903.03$-324.48$-11.29$-1.21$-0.63
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0M$15.0M$4.0M$20.0M$27.0M
Total Liabilities$7.0M$3.0M$6.0M$5.0M$6.0M
Cash$6.0M$14.0M$4.0M$13.0M$4.0M
Borrowings$1.0M$0$2.0M$0$1.0M

Latest News

TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML MT Newswires · Jun 15, 2026 TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers PR Newswire · Jun 15, 2026 HURA: Refining TBS-2025 Development Plan Zacks Small Cap Research · May 26, 2026 TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire · May 15, 2026 TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR Newswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-8.0M$-12.0M$-15.0M$-28.0M
Investing Cash Flow$0$0$-1.0M$-6.0M$-1.0M
Financing Cash Flow$0$0$0$-4.0M$-3.0M
Net Cash Flow$0$9.0M$-11.0M$9.0M$-9.0M
Free Cash Flow$-7.0M$-8.0M$-12.0M$-15.0M$-28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-4.91
FCF Yield-18.23%
Quick Ratio1.15
Interest Coverage-32.00
Return 1Y2.15%
Return 3Y-98.53%
Return 5Y-99.92%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
INO $1.04 +0.97% -2.73 $55.73M 0.00%
IRDOpus Genetics, Inc. $3.32 +7.63% -2.35 $273.71M 0.00%

About HURA

HURA is led by CEO James A. Bianco, employs 19 people, headquartered in US, publicly traded since 2013.

HURA stock trades at $2.09 with a market capitalization of $133.10M. The stock is valued at a price-to-earnings (P/E) ratio of -3.75, price-to-book of 6.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.41 and $3.90, and currently trades 46.4% below its 52-week high.

On profitability, HURA generates a return on equity (ROE) of -187.16%, return on capital employed of -152.38%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides